March 13 (Reuters) – The collapse of Silicon Valley Bank (SIVB.O) will leave early-stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly-traded drug companies should escape unscathed. About 50% of U.S. biotech companies, developing drugs for everything from cancer to heart disease and rare conditions, banked with Silicon Valley Bank […]

Despite missing the initial mark, Clene Inc.’s gold nanocrystal therapy for ALS still shows promise. Thursday, the company shared new results from an exploratory analysis showing CNM-Au8 delayed disease progression across key areas for patients. In October 2022, Clene reported that CNM-Au8 did not meet the primary endpoint of slope of change in the HEALEY ALS trial based on the adjusted […]

Newly announced 6-month findings from the HEALEY-ALS Platform trial, the first of its kind for amyotrophic lateral sclerosis (ALS), showed that treatment with CNM-Au8 (Clene Nanomedicine) was tolerable, with several meaningful delays in clinical worsening and increased survival benefit.1 CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by […]